Core Viewpoint - The recent policy document issued by multiple government departments aims to promote high-quality development in the pharmaceutical retail industry, leading to a surge in stock prices of major pharmacy chains in the A-share market [1][3]. Group 1: Policy Measures - The policy document outlines 18 specific measures to enhance the pharmaceutical retail sector, focusing on professionalization, digitalization, and regulatory compliance [1]. - Key initiatives include improving pharmacy service capabilities, supporting mergers and acquisitions among retail pharmacies, and fostering a fair competitive market environment [2]. Group 2: Market Impact - The policy is expected to drive mergers and acquisitions, increasing industry concentration and facilitating the transition of pharmacies from "drug sales" to "comprehensive services" [2]. - Leading pharmacy chains such as Yifeng Pharmacy and Dacelins have seen significant stock price increases, with Yifeng's store count projected to exceed 14,666 by September 2025, and Dacelins operating 17,385 stores [3]. Group 3: Benefits to Other Companies - Other pharmaceutical companies like Shanghai Pharmaceuticals, China Resources Pharmaceutical, and Jiuzhoutong are anticipated to benefit from the integration of wholesale and retail operations, enhancing their revenue potential [3]. - The policy encourages retail pharmacies to enhance their service capabilities, which may benefit digital and supply chain service providers in the healthcare sector [4].

Core Viewpoint - Shanghai Pharmaceuticals (02607.HK) announced that its subsidiary, Changzhou Pharmaceutical Factory, has received a drug registration certificate from the Health Sciences Authority (HSA) of Singapore for Pregabalin capsules, which have been approved for market launch [1] Group 1 - The approved drug, Pregabalin capsules, is primarily used for the treatment of postherpetic neuralgia, diabetic peripheral neuropathy, fibromyalgia, and neuropathic pain due to spinal cord injury, as well as for adjunctive treatment of epilepsy [1]

香港交易及結算所有限公司和香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因依賴 該等內容而引致的任何損失承擔任何責任。 上 海 醫 藥 集 團 股 份 有 限 公 司 Shanghai Pharmaceuticals Holding Co., Ltd. * 承董事會命 上海醫藥集團股份有限公司 楊秋華 董事長 中國上海，2026 年 1 月 24 日 於本公告日期，本公司的執行董事為楊秋華先生、沈波先生、李永忠先生及董明 先生；非執行董事為張文學先生；以及獨立非執行董事為顧朝陽先生、霍文遜先 生、王忠先生及萬鈞女士。 * 僅供識別 （於中華人民共和國註冊成立的股份有限公司） （股份代碼：02607） 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第 13.10B 條而作出。 茲載列上海醫藥集團股份有限公司（「本公司」）在上海證券交易所網站(http://www.sse.com.cn) 刊登的《上海醫藥集團股份有限公司關於普瑞巴林膠囊獲得新加坡藥品註冊證書的公告》、 《上海醫藥集團股份有限公司關於馬來酸阿伐曲 ...

证券代码：601607 证券简称：上海医药 编号：临 2026-007 上海医药集团股份有限公司 关于马来酸阿伐曲泊帕片获得批准生产的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 近日，上海医药集团股份有限公司（以下简称"公司"）下属上海上药信谊 药厂有限公司（以下简称"上药信谊"）的马来酸阿伐曲泊帕片（以下简称"该 药品"）收到国家药品监督管理局（以下简称"国家药监局"）颁发的《药品注 册证书》（证书编号：2026S00156），该药品获得批准生产。 一、该药品基本情况 药品名称：马来酸阿伐曲泊帕片 剂型：片剂 规格：20mg（以 C29H34Cl2N6O3S2计） 注册分类：化学药品 4 类 药品批准文号：国药准字 H20263130 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，本品 符合药品注册的有关要求，批准注册，发给药品注册证书。 二、该药品相关的信息 1 IQVIA 数据库显示，2024 年中国大陆医院采购马来酸阿伐曲泊帕片的金额 为人民币 56,656 万元。 三、对上市公司影响及 ...

证券代码：601607 证券简称：上海医药 编号：临2026-006 上海医药集团股份有限公司 关于普瑞巴林胶囊获得新加坡药品注册证书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 近日，上海医药集团股份有限公司（以下简称"上海医药"或"公司"）下 属常州制药厂有限公司（以下简称"常州制药厂"）生产的普瑞巴林胶囊（以下 简称"该药品"）收到新加坡食品药品监督管理局（HSA）颁发的药品注册证书， 该药品获得批准上市。 一、该药品基本情况 药品名称：普瑞巴林胶囊 剂型：胶囊 规格：50mg、75mg、150mg 注册分类：化学仿制药 生产厂家：常州制药厂有限公司 注册证号：50mg：SIN17444P；75mg：SIN17443P；150mg：SIN17442P 二、该药品相关的信息 普瑞巴林胶囊主要用于治疗带状疱疹后神经痛、糖尿病外周神经痛、纤维肌 痛和脊髓损伤引起的神经性疼痛以及癫痫的辅助治疗。 2019 年 10 月，常州制药厂完成普瑞巴林胶囊的研发工作；2021 年 7 月，该 药品获得美国食品药品监督管理局 ...

Core Viewpoint - Shanghai Pharmaceuticals (601607.SH) has received approval from the National Medical Products Administration for the production of Maleate Avatrombopag Tablets, which are indicated for adult patients with chronic liver disease-related thrombocytopenia and chronic primary immune thrombocytopenia (ITP) [1] Group 1: Product Approval - The Maleate Avatrombopag Tablets are approved for use in adult patients undergoing elective diagnostic procedures or surgeries related to chronic liver disease [1] - The product is also suitable for adult patients with chronic primary immune thrombocytopenia who have previously shown poor response to treatments such as corticosteroids and immunoglobulins [1] - The drug was originally developed by AkaRx Inc. in the United States and was launched in the U.S. market in 2018 [1] Group 2: Development and Investment - Shanghai Pharmaceuticals submitted the registration application for the drug to the National Medical Products Administration in August 2024, which has been accepted [1] - As of the date of the announcement, the company has invested approximately RMB 9.8961 million in the research and development of this product [1] Group 3: Market Competition - The main domestic manufacturers of this drug in China include Fosun Pharma (Jiangsu) Pharmaceutical Group Co., Ltd., Nanjing Zhengda Tianqing Pharmaceutical Co., Ltd., and Qilu Pharmaceutical Co., Ltd. [1]

Core Viewpoint - Shanghai Pharmaceuticals (601607) has received regulatory approvals for two of its products, indicating a positive development in its product pipeline and potential for revenue growth [1]. Group 1: Product Approvals - The company's subsidiary, Shanghai Pharmaceuticals Holding Co., Ltd., has obtained a Drug Registration Certificate from the National Medical Products Administration for its drug, Avatrombopag Maleate Tablets, allowing it to commence production [1]. - Additionally, the company's Changzhou Pharmaceutical Factory has received a Drug Registration Certificate from the Health Sciences Authority of Singapore for its drug, Prucalopride Capsules, enabling it to be marketed [1].

Core Viewpoint - Shanghai Pharmaceuticals (601607.SH) has received a drug registration certificate from the Health Sciences Authority (HSA) of Singapore for its Pregabalin capsules, allowing the product to be marketed [1] Group 1: Product Approval - The Pregabalin capsules are primarily used for treating postherpetic neuralgia, diabetic peripheral neuropathy, fibromyalgia, spinal cord injury-related neuropathic pain, and as an adjunct therapy for epilepsy [1] - The product's research and development were completed by Changzhou Pharmaceutical Factory in October 2019, and it received approval from the U.S. Food and Drug Administration in July 2021 [1] Group 2: Market Expansion - The Pregabalin capsules also received approval from the Thai Food and Drug Administration for market entry by June 2025 [1] - The company has invested approximately RMB 2.19 million in research and development for the product's launch in Southeast Asian markets, including Thailand, Singapore, Malaysia, and the Philippines [1]

Core Viewpoint - Shanghai Pharmaceuticals' subsidiary, Changzhou Pharmaceutical Factory, has received a drug registration certificate from the Health Sciences Authority (HSA) of Singapore for the launch of Pregabalin capsules, indicating a significant milestone in the company's product portfolio expansion in Southeast Asia [1] Group 1: Product Approval and Indications - Pregabalin capsules are approved for the treatment of postherpetic neuralgia, diabetic peripheral neuropathy, fibromyalgia, spinal cord injury-related neuropathic pain, and as an adjunctive treatment for epilepsy [1] - The drug development for Pregabalin capsules was completed by Changzhou Pharmaceutical Factory in October 2019, and it received approval from the U.S. Food and Drug Administration (FDA) in July 2021 [1] Group 2: Market Expansion and Investment - The approval in Singapore follows the drug's approval in Thailand in June 2025, indicating a strategic focus on expanding into Southeast Asian markets, including Thailand, Singapore, Malaysia, and the Philippines [1] - The company has invested approximately RMB 2.19 million in research and development for this drug in the Southeast Asian market as of the date of the announcement [1]

Market Performance - The pharmaceutical commercial sector increased by 0.94% on January 22, with Huaren Health leading the gains [1] - The Shanghai Composite Index closed at 4122.58, up 0.14%, while the Shenzhen Component Index closed at 14327.05, up 0.5% [1] Individual Stock Performance - Huaren Health (301408) closed at 23.17, up 6.24% with a trading volume of 347,100 shares and a transaction value of 781 million [1] - Jiyu Pingmin (301017) closed at 17.71, up 4.67% with a trading volume of 188,800 shares and a transaction value of 328 million [1] - Mushi Tang (002462) closed at 16.89, up 4.65% with a trading volume of 205,900 shares and a transaction value of 344 million [1] - Other notable stocks include Yizheng Medical (002788) up 3.14% and Dajia Weikang (301126) up 3.11% [1] Capital Flow Analysis - The pharmaceutical commercial sector experienced a net outflow of 82.14 million from institutional investors, while retail investors saw a net inflow of 5.87 million [2] - The sector's overall capital flow indicates a mixed sentiment, with institutional investors withdrawing funds while retail investors are entering the market [2] Detailed Capital Flow for Selected Stocks - Jiyu Pingmin had a net inflow of 20.13 million from institutional investors, while retail investors had a net outflow of 40.72 million [3] - Huaren Health saw a net inflow of 28.31 million from institutional investors and a net outflow of 60.37 million from retail investors [3] - Mushi Tang had a net inflow of 42.17 million from institutional investors, but retail investors experienced a net outflow of 43.09 million [3]